These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1778870)

  • 21. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
    Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
    J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.
    Fung-Tomc JC; Gradelski E; Huczko E; Dougherty TJ; Kessler RE; Bonner DP
    Antimicrob Agents Chemother; 1996 May; 40(5):1289-93. PubMed ID: 8723487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects on beta-lactam susceptibility of phenotypic induction and genotypic derepression of beta-lactamase synthesis.
    Shannon K; Phillips I
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():15-22. PubMed ID: 3102451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer].
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K
    Cas Lek Cesk; 1997 Mar; 136(5):154-6. PubMed ID: 9221190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.
    Szabó D; Bonomo RA; Silveira F; Pasculle AW; Baxter C; Linden PK; Hujer AM; Hujer KM; Deeley K; Paterson DL
    J Clin Microbiol; 2005 Oct; 43(10):5058-64. PubMed ID: 16207962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of resistance to cephalosporins in clinical strains of Citrobacter spp.
    Gootz TD; Jackson DB; Sherris JC
    Antimicrob Agents Chemother; 1984 May; 25(5):591-5. PubMed ID: 6610388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility evolution to antibiotics of Enterobacter cloacae, Morganella morganii, Klebsiella aerogenes and Citrobacter freundii involved in urinary tract infections: an 11-year epidemiological surveillance study.
    Jiménez-Guerra G; Borrego-Jiménez J; Gutiérrez-Soto B; Expósito-Ruiz M; Navarro-Marí JM; Gutiérrez-Fernández J
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Apr; 38(4):166-169. PubMed ID: 31606242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of beta-lactamase inducibility and derepression on the activity of cefpirome against gram-negative bacteria.
    Chen HY; Livermore DM
    J Antimicrob Chemother; 1993 Oct; 32(4):651-2. PubMed ID: 8288508
    [No Abstract]   [Full Text] [Related]  

  • 31. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
    Neu HC; Chin NX; Jules K; Labthavikul P
    J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins.
    Hancock RE; Bellido F
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():1-6. PubMed ID: 1601751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro study of antibacterial activity of cefepime (Axepim) against gram negative bacteria: comparison with cephalosporins and other beta-lactams].
    Vachée A; Devalckenaere A; Husson MO; Izard D
    Pathol Biol (Paris); 1996 Feb; 44(2):132-7. PubMed ID: 8761598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cefepime (maxipime), large spectrum 4th generation cephalosporin, resistant to beta-lactamases].
    Angelescu M; Apostol A
    Chirurgia (Bucur); 2001; 96(6):547-52. PubMed ID: 12731231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime.
    Vakulenko SB; Golemi D; Geryk B; Suvorov M; Knox JR; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1966-70. PubMed ID: 12019116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.